Please assess the completion status of the following clinical trial:

Trial Title: GLPG2737 on Top of Orkambi in Subjects With Cystic Fibrosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female subject ≥18 years of age on the day of signing the ICF.~* A confirmed clinical diagnosis of CF and homozygous for the F508del CFTR mutation.~* Stable intake of physician prescribed Orkambi (lumacaftor 400 mg/ivacaftor 250 mg b.i.d.) for at least 12 weeks prior to the first study drug administration, and planned continuation of Orkambi for the duration of the study.~* FEV1 ≥40% of predicted normal for age, gender and height at screening (pre- or postbronchodilator).~* Sweat chloride concentration ≥60 mmol/L at screening.~Exclusion Criteria:~* History of serious allergic reaction to any drug as determined by the investigator (e.g., anaphylaxis requiring hospitalization) and/or known sensitivity to any component of the study drug.~* History of clinically meaningful unstable or uncontrolled chronic disease that makes the subject unsuitable for inclusion in the study in the opinion of the investigator.~* Unstable pulmonary status or respiratory tract infection (including rhinosinusitis) requiring a change in therapy within 4 weeks prior to the first study drug administration.~* History of hepatic cirrhosis with portal hypertension (e.g.,signs/symptoms of splenomegaly, esophageal varices, etc.).~* Abnormal liver function test at screening, defined as aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) and/or alkaline phosphatase and/or gammaglutamyl transferase (GGT) ≥3 x the upper limit of normal (ULN), and/or total bilirubin ≥1.5 x the ULN at screening.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- GLPG2737 (Type: EXPERIMENTAL): GLPG2737 will be provided as capsules for oral use.
- Placebo (Type: PLACEBO_COMPARATOR): Placebo will be provided as capsules for oral use.

Based on this trial design, predict the completion outcome and termination type (if applicable).